Stine Overvad Fredslund1, Agnethe Berglund2,3, Anders Bonde Jensen4, Britt Elmedal Laursen4,3,5, Svend Juul6, Kirstine Stochholm7, Claus Højbjerg Gravholt3,7. 1. Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. stin.fred@auh.rm.dk. 2. Department of Clinical Genetics, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. 3. Department of Molecular Medicine (MOMA), Aarhus University Hospital, Brendstrupgårdsvej 100, 8200, Aarhus N, Denmark. 4. Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. 5. Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 3, 8000, Aarhus C, Denmark. 6. Department of Public Health, Aarhus University, Bartholins Allé 2, 8000, Aarhus C, Denmark. 7. Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Abstract
BACKGROUND: Cardiovascular disease competes with breast cancer (BC) as the leading cause of death for females diagnosed with breast cancer. Not much is known concerning morbidity and medicine use in the short and long term after a BC diagnosis. AIM: The aim of this study was to determine acute and long-term morbidity in Danish women treated for BC. METHOD: A nationwide registry-based cohort study of 100,834 BC patients identified in the clinical database of Danish Breast Cancer Cooperative Group (DBCG) and 1,100,320 (10 per patient) age-matched Danish women without BC, serving as controls. Morbidity was studied using complete data on hospital contacts and medicinal use. RESULTS: The risk of hospital contacts was significantly increased in BC survivors compared with controls evaluated both by means of Cox regression and negative binomial regression analysis both during and after cessation of breast cancer treatment. Young age at breast cancer diagnosis was associated with the most pronounced increase in risk of hospital contacts, both during and after cessation of BC treatment. Medicinal use was significantly increased among BC patients compared to controls, both during (HR 1.27 (1.26-1.28), p < 0.0001) and after BC treatment (HR 1.18 (1.17-1.19), p < 0.0001, and present for all subgroups of medicine. CONCLUSION: Overall, BC survivors have a pronounced increase in hospital contacts and medicinal use compared to women without BC. Premenopausal status at BC diagnosis was associated with an overall higher excess morbidity and a higher burden both during and after treatment.
BACKGROUND: Cardiovascular disease competes with breast cancer (BC) as the leading cause of death for females diagnosed with breast cancer. Not much is known concerning morbidity and medicine use in the short and long term after a BC diagnosis. AIM: The aim of this study was to determine acute and long-term morbidity in Danish women treated for BC. METHOD: A nationwide registry-based cohort study of 100,834 BC patients identified in the clinical database of Danish Breast Cancer Cooperative Group (DBCG) and 1,100,320 (10 per patient) age-matched Danish women without BC, serving as controls. Morbidity was studied using complete data on hospital contacts and medicinal use. RESULTS: The risk of hospital contacts was significantly increased in BC survivors compared with controls evaluated both by means of Cox regression and negative binomial regression analysis both during and after cessation of breast cancer treatment. Young age at breast cancer diagnosis was associated with the most pronounced increase in risk of hospital contacts, both during and after cessation of BC treatment. Medicinal use was significantly increased among BC patients compared to controls, both during (HR 1.27 (1.26-1.28), p < 0.0001) and after BC treatment (HR 1.18 (1.17-1.19), p < 0.0001, and present for all subgroups of medicine. CONCLUSION: Overall, BC survivors have a pronounced increase in hospital contacts and medicinal use compared to women without BC. Premenopausal status at BC diagnosis was associated with an overall higher excess morbidity and a higher burden both during and after treatment.
Authors: E B Gold; J Bromberger; S Crawford; S Samuels; G A Greendale; S D Harlow; J Skurnick Journal: Am J Epidemiol Date: 2001-05-01 Impact factor: 4.897
Authors: Jann Arends; Patrick Bachmann; Vickie Baracos; Nicole Barthelemy; Hartmut Bertz; Federico Bozzetti; Ken Fearon; Elisabeth Hütterer; Elizabeth Isenring; Stein Kaasa; Zeljko Krznaric; Barry Laird; Maria Larsson; Alessandro Laviano; Stefan Mühlebach; Maurizio Muscaritoli; Line Oldervoll; Paula Ravasco; Tora Solheim; Florian Strasser; Marian de van der Schueren; Jean-Charles Preiser Journal: Clin Nutr Date: 2016-08-06 Impact factor: 7.324
Authors: W Demark-Wahnefried; B L Peterson; E P Winer; L Marks; N Aziz; P K Marcom; K Blackwell; B K Rimer Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Patrick T Bradshaw; June Stevens; Nikhil Khankari; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon Journal: Epidemiology Date: 2016-01 Impact factor: 4.822
Authors: Sofie A M Gernaat; Jolanda M A Boer; Desiree H J van den Bongard; Angela H E M Maas; Carmen C van der Pol; Rhodé M Bijlsma; Diederick E Grobbee; Helena M Verkooijen; Petra H Peeters Journal: Breast Cancer Res Treat Date: 2018-02-28 Impact factor: 4.872
Authors: Christina M Dieli-Conwright; Louise Wong; Sarah Waliany; Leslie Bernstein; Behrouz Salehian; Joanne E Mortimer Journal: Cancer Date: 2016-05-24 Impact factor: 6.860